Alcami's Strategic Acquisition in the Biologics Sector
Alcami Corporation has made a significant investment to enhance its capabilities in biologics by acquiring a spacious facility in the heart of a key development area. This recent move showcases Alcami's commitment to providing cutting-edge contract development and manufacturing services as a prominent U.S.-based CDMO.
Details of the Facility Acquisition
The newly acquired facility, spanning 37,000 square feet, is located at 4620 Creekstone Drive in its industry-focused area. This acquisition represents a substantial investment of $6.7 million, aimed at bolstering Alcami’s infrastructure and service offerings. The facility is designed to cater to the evolving demands of the biopharmaceutical industry, particularly within the realm of biologics.
Expanding Analytical and Development Capabilities
The facility will act as a focal point for Alcami's expanding analytical and development functions. Plans are underway for a significant lab expansion that is anticipated to be completed within the coming months. This enhancement will facilitate Alcami's support for complex therapeutics, including biologics, peptides, proteins, oligonucleotides, and emerging fields like cell and gene therapy drug substances.
Strategic Goals and Future Prospects
Alcami’s President of Lab Operations, Katie Schlipp, emphasized the importance of this acquisition: "This acquisition marks another milestone in our strategy to deliver innovative, scalable solutions for our clients in the growing area of biologics. By expanding our analytical lab capabilities in RTP, we're able to support innovators in bringing life-changing therapies to patients faster and more reliably."
Integration with Existing Operations
The new facility complements Alcami’s existing lab operations and commercial manufacturing capabilities, which include sterile fill-finish services and cGMP storage within the RTP area. With this strategic investment, Alcami aims to mitigate supply chain risks while providing advanced solutions that streamline the drug development process.
Commitment to Drug Development
Recently, Alcami confirmed the qualification of a third sterile fill-finish line at its campus in RTP. This addition increases its total to five qualified GMP-compliant lines dedicated to clinical and commercial manufacturing. Such expansions are integral to supporting Alcami's mission of advancing drug development and ensuring a reliable supply of essential therapies for patients.
Alcami's Comprehensive Services
With over 45 years of experience in the field, Alcami Corporation is dedicated to advancing pharmaceuticals and biologics from development to delivery. They offer a comprehensive suite of integrated lab services, drug product manufacturing, and cGMP storage solutions. Their ownership structure includes notable private equity partners such as GHO Capital and The Vistria Group, enhancing their capabilities in the pharmaceutical landscape.
Learn More About Alcami
To gain deeper insights into Alcami's broad range of services and innovations in drug development, interested parties are encouraged to explore their official website.
Frequently Asked Questions
What is the purpose of Alcami's new facility?
The facility will expand Alcami's capabilities in analytical and development services focusing on biologics and complex therapeutics.
How much did Alcami invest in the new facility?
Alcami invested $6.7 million in the acquisition of the new facility located in Durham.
What are some of the services offered by Alcami?
Alcami provides integrated lab services, drug product manufacturing, cGMP storage, and development support for biopharmaceuticals.
Where is Alcami headquartered?
Alcami Corporation is headquartered in North Carolina, offering services across the United States.
What advancements has Alcami recently made in their operations?
Alcami recently qualified a third sterile fill-finish line, expanding their capacity for clinical and commercial manufacturing.
